statements

Sandu Pharmaceuticals Ltd.

BSE: 524703

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

39.30+0.0 (+0.03%)

27 Jul, 3:29 PM

Overview Analysis Statements

Technicals Forecast Peers Resources News

Income Statement

Abridged

Understanding Income Statement

Sandu Pharmaceuticals Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	49.02	49.42	48.37	58.76	65.50	65.35	67.28	67.19	69.93
Cost of Operating Revenue	29.00	25.95	25.67	35.06	36.27	31.71	33.15	32.77	32.25
Gross Profit	20.02	23.48	22.70	23.70	29.23	33.64	34.13	34.42	37.69
Gross Margin	40.8	47.5	46.9	40.3	44.6	51.5	50.7	51.2	53.9
Total Operating Expenses	47.15	47.97	47.46	57.15	63.16	63.38	65.57	65.10	67.61
Operating Profit	1.86	1.46	0.90	1.60	2.34	1.97	1.71	2.09	2.32
Operating Margin	3.8	3.0	1.9	2.7	3.6	3.0	2.5	3.1	3.3
Financing Income/(Expense) - Net	-1.23	-1.01	-0.43	-0.11	-0.11	-0.08	-0.06	-0.10	-0.11
Profit before Taxes	0.76	1.02	0.92	1.68	2.32	2.22	2.07	2.16	2.66
Income Taxes	0.19	0.35	0.20	0.59	0.73	0.70	0.61	0.61	0.89
Profit after Tax	0.56	0.67	0.72	1.09	1.59	1.52	1.46	1.55	1.77
PAT Margin	1.1	1.4	1.5	1.9	2.4	2.3	2.2	2.3	2.5
EPS - Basic - ex Extraordinary Items	0.79	0.94	1.02	1.54	1.99	1.61	1.51	1.60	1.83
EPS - Diluted - ex Extraordinary Items	0.79	0.94	1.02	1.54	1.87	1.61	1.51	1.60	1.83
EBIT	1.86	1.46	0.90	1.60	2.34	1.97	1.71	2.09	2.32
EBITDA	2.47	2.09	1.46	2.16	2.87	2.49	2.30	2.76	3.51
EBITDA Margin	5.0	4.2	3.0	3.7	4.4	3.8	3.4	4.1	5.0

Balance Sheet

Abridged

Understanding Balance Sheet

Sandu Pharmaceuticals Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	20.83	20.08	22.42	30.54	23.65	25.54	22.30	26.30	25.32
Long-Term Investments	1.12	1.13	0.82	0.25	9.15	11.58	12.23	11.27	12.33
Property Plant & Equipment - Net	17.41	16.92	16.50	16.11	16.45	16.99	17.84	18.12	18.17
Total Non-Current Assets	23.69	23.56	18.99	16.42	25.64	28.62	30.11	29.42	30.55
Total Assets	44.53	43.64	41.41	46.96	49.28	54.17	52.41	55.72	55.87
Total Current Liabilities	15.38	13.86	11.33	12.52	11.87	13.88	10.64	12.09	10.42
Long Term Debt	0.25	0.18	-	-	-	-	0.06	0.42	0.31
Total Non-Current Liabilities	1.06	0.99	0.85	0.95	0.94	1.04	1.18	1.62	1.77
Total Liabilities	16.44	14.85	12.18	13.47	12.81	14.93	11.82	13.70	12.20
Total Shareholders' Equity	28.08	28.79	29.24	33.49	36.47	39.24	40.59	42.02	43.67
Total Equity	28.08	28.79	29.24	33.49	36.47	39.24	40.59	42.02	43.67
Total Liabilities & Equity	44.53	43.64	41.41	46.96	49.28	54.17	52.41	55.72	55.87

Cash Flow

Abridged

Understanding Cash Flow Statement

Sandu Pharmaceuticals Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2018 Mar 31	2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	2.27	2.40	1.76	2.04	2.16	2.15	2.14	2.38	3.26
Working Capital - Increase/(Decrease)	-1.01	1.35	4.47	5.75	-1.13	-1.77	-1.22	-1.32	2.91
Net CF from Operating Activities	1.26	3.75	6.22	7.78	1.03	0.38	0.92	1.06	6.17
Capital Expenditures - Net	0.63	0.11	0.11	0.13	0.84	1.07	1.43	0.94	0.72
Net CF from Investing Activities	-0.64	-0.11	-0.39	-5.77	-5.55	0.38	-1.47	-0.29	-0.63
Dividends Paid - Cash - Total	-	-	-	-	0.32	0.66	0.72	0.77	0.77
Stock - Issuance/(Retirement) - Net	-	-	-	1.74	1.38	1.32	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	-0.66	-3.25	-4.92	-1.23	-0.02	-	0.06	0.41	-0.06
Net Cash Flow from Financing Activities	-1.89	-4.26	-5.36	1.30	0.93	0.58	-0.72	-0.46	-0.94
Free Cash Flow to Equity	-0.04	0.39	1.19	6.43	0.17	-0.69	-0.44	0.54	5.40
Free Operating CF net dividend	0.58	3.64	6.11	7.66	-0.13	-1.35	-1.23	-0.65	4.68
Free Operating CF	0.58	3.64	6.11	7.66	0.19	-0.69	-0.51	0.12	5.45

Business Segment Analysis

Sandu Pharmaceuticals Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

We don't have enough data to show business segment analysis for Sandu Pharmaceuticals Ltd.

Regional Segment Analysis

Sandu Pharmaceuticals Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Sandu Pharmaceuticals Ltd.

Historical Segment Analysis

Track how Sandu Pharmaceuticals Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

We don't have enough data to show segments for Sandu Pharmaceuticals Ltd.

Frequently Asked Questions

What is the revenue of Sandu Pharmaceuticals Ltd.?

The latest trailing twelve month revenue of Sandu Pharmaceuticals Ltd. is ₹ 69.93 Cr, reflecting a 1-year growth of 4.08% and a 3-year CAGR of 2.29%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Sandu Pharmaceuticals Ltd.?

The latest trailing twelve month net profit (PAT) of Sandu Pharmaceuticals Ltd. is ₹ 1.77 Cr, with a 3-year earnings CAGR of 4.32%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Sandu Pharmaceuticals Ltd.?

The trailing twelve month EBITDA of Sandu Pharmaceuticals Ltd. is approximately ₹ 2.32 Cr (based on an operating margin of 3.32%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Sandu Pharmaceuticals Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Sandu Pharmaceuticals Ltd. is 1.83. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Sandu Pharmaceuticals Ltd.?

The debt-to-equity ratio of Sandu Pharmaceuticals Ltd. stands at 0.01. The interest coverage ratio is 20.74x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Sandu Pharmaceuticals Ltd.?

The estimated book value per share of Sandu Pharmaceuticals Ltd. is 45.22 (derived from a P/B ratio of 0.87 and market price of ₹ 39.30), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Sandu Pharmaceuticals Ltd.?

The trailing twelve month operating cash flow of Sandu Pharmaceuticals Ltd. is ₹ 6.17 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Sandu Pharmaceuticals Ltd. report consolidated or standalone financials?

Sandu Pharmaceuticals Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.